Comparison of the hematological effects of a sustained release chitosan formulation of pentoxifylline with a commercial formulation

Yamac K., Kaptan K., Beyan C., Teksin Z. Ş., Agabeyoglu I., Gokgoz L.

ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH, cilt.50, sa.9, ss.827-831, 2000 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 50 Sayı: 9
  • Basım Tarihi: 2000
  • Doi Numarası: 10.1055/s-0031-1300296
  • Dergi Adı: ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.827-831
  • Gazi Üniversitesi Adresli: Evet

Özet

In the present study the hematological effects of a sustained release chitosan formulation of pentoxifylline (CAS 6493-05-6) were examined and compared with those of a commercial product. The study was carried out on 12 healthy volunteers. Both formulations were tolerated well clinically. The results demonstrated no antiaggregatory effect of the two different formulations of pentoxifylline in platelet rich plasma. Both drugs resulted in a decrease of plasma fibrinogen levels. A remarkable side effect of the new formulation was mild basophilia, without any clinical problems.